Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer:: Findings from the British Women's Heart and Health Study

被引:54
作者
Heikkila, Katriina
Ebrahim, Shah
Rumley, Ann
Lowe, Gordon
Lawlor, Debbie A.
机构
[1] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England
[2] London Sch Hyg & Trop Med, London WC1, England
[3] Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
关键词
D O I
10.1158/1055-9965.EPI-07-0093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Inflammation is associated with worse prognosis and survival in many cancers. Our aim was to investigate the associations of circulating C-reactive protein (CRP) and interleukin-6 (IL-6) concentrations with all-cause mortality in cancer patients and to determine whether any associations were specific to malignancy. Method: We used data from the British Women's Heart and Health Study, a cohort of 4,286 women aged 60 to 79 years. We investigated the associations between CRP, IL-6, and survival in women with and without cancer using Cox regression and assessed the interaction between cancer status and these inflammatory markers to determine whether these associations differed according to cancer status. Results: Elevated CRP and IL-6 were associated with decreased survival in women with cancer [unadjusted hazard ratio per doubling of CRP, 1.22, 95% confidence interval (95% CI), 1.03, 1.46; and per doubling of IL-6, 1.52, 95% CI, 1.25, 1.86] and in women without cancer [CRP: 1.24 (1.12, 1.37); IL-6: 1.53 (1.35, 1.75)]. Adjustment for age, body mass index, physical activity level, socioeconomic position, HRT use, and tobacco smoking did not change these associations. After mutual adjustment, IL-6 but not CRP was independently associated with survival. We found no strong evidence that these associations differed between cancer patients and cancer-free women. Conclusions: Elevated CRP and IL-6 concentrations were similarly associated with an increased risk of death in elderly women with and without cancer. Thus, in this group, these markers are likely to be indicators of non-cancer comorbidities rather than related to the malignancy itself.
引用
收藏
页码:1155 / 1159
页数:5
相关论文
共 19 条
[11]   Associations of adult measures of childhood growth with breast cancer: findings from the British Women's Heart and Health Study [J].
Lawlor, DA ;
Okasha, M ;
Gunnell, D ;
Smith, GD ;
Ebrahim, S .
BRITISH JOURNAL OF CANCER, 2003, 89 (01) :81-87
[12]   Socioeconomic position in childhood and adulthood and insulin resistance: cross sectional survey using data from British women's heart and health study [J].
Lawlor, DA ;
Ebrahim, S ;
Smith, GD .
BRITISH MEDICAL JOURNAL, 2002, 325 (7368) :805-807
[13]   Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease [J].
Lowe, GDO .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (08) :1618-1627
[14]   Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer [J].
McArdle, Peter A. ;
Mir, Khurram ;
Almushatat, A. S. K. ;
Wallace, A. Michael ;
Underwood, Mark A. ;
McMillan, Donald C. .
UROLOGIA INTERNATIONALIS, 2006, 77 (02) :127-129
[15]   Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer [J].
McMillan, DC ;
Elahi, MM ;
Sattar, N ;
Angerson, WJ ;
Johnstone, J ;
McArdle, CS .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2001, 41 (1-2) :64-69
[16]  
Nikiteas NI, 2005, WORLD J GASTROENTERO, V11, P1639
[17]   Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico-pathological features and prognosis [J].
Rutkowski, P ;
Kaminska, J ;
Kowalska, M ;
Ruka, W ;
Steffen, J .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (04) :463-471
[18]   SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH PROGNOSIS IN DIFFUSE LARGE-CELL LYMPHOMA [J].
SEYMOUR, JF ;
TALPAZ, M ;
CABANILLAS, F ;
WETZLER, M ;
KURZROCK, R .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :575-582
[19]   The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma [J].
Tas, F ;
Oguz, H ;
Argon, A ;
Duranyildiz, D ;
Camlica, H ;
Yasasever, V ;
Topuz, E .
MEDICAL ONCOLOGY, 2005, 22 (03) :241-246